My understanding is that they're still working on collecting the A/R- just listing it as a massive write-down in case they're not successful. Also an opportunity for new CEO to start with a clean slate...But things do look particularly grim.
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution
